RxDoctor Payments Data

Meredith Hawthorne, PA

Medical · Jacksonville, FLNPI 1588009674

Payments from drug & device makers

$7,063in general payments, 2019–2025

Across 75 payments — averaging $94.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$5K
  • AbbVie$839
  • Acadia Pharmaceuticals Inc$369
  • MDD US Operations, LLC$164
  • Biohaven Pharmaceuticals, Inc.$143
  • Boston Scientific$121
  • plus $356 from 7 others

What the payments were for

  • Consulting fees$3,15045%
  • Travel & lodging$1,33719%
  • Food & beverage$2,48435%
  • Education$921%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,063 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$3,878
Medicare patients
30
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$122,672
RytaryCarbidopa/Levodopa110$110,398
AustedoDeutetrabenazine12$55,653
GocovriAmantadine Hcl14$36,712
UbrelvyUbrogepant21$34,437
Emgality PenGalcanezumab-Gnlm17$11,948
Carbidopa-LevodopaCarbidopa/Levodopa216$7,160
Gabapentin303$4,882
RivastigmineRivastigmine Tartrate56$4,634
Tramadol Hcl139$1,971
Primidone87$1,962
Pregabalin86$1,815
Carbidopa-Levodopa ErCarbidopa/Levodopa56$1,784
AmantadineAmantadine Hcl29$1,714
Memantine Hcl57$1,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$21$122,67215 claims
MDD US Operations, LLCGocovri$164$36,71214 claims
AbbVieUbrelvy$839$34,43721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.

Other medical in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →